I-Mab Biopharma Co., Ltd. - Utang jangka cendhak perusahaan IMAB

The price characteristics of I-Mab (IMAB) on the GURU.Markets platform, where the indicator stands at 0.00, reflect a company developing a broad spectrum of anti-tumor agents. The sale of local stakes and the optimization of its capital structure have provided the financial stability necessary to conduct global trials. Meanwhile, the business relies on costly temperature control during drug transportation, which is critical for maintaining their efficacy.

IMAB (I-Mab) riwayat Utang jangka cendhak perusahaan saka 04.07.2022 nganti 30.10.2025

I-Mab Biopharma Co., Ltd. - rincian analitis lan metrik utama (IMAB)

- rega lan prakiraan konsensus rega:

Rega saham I-Mab Inc.|IMAB - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar I-Mab Biopharma|IMAB - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Nilai Buku saben Saham I-Mab|IMAB - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku i-mabbiopharma.com|IMAB - Aset Agregat Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas I-Mab|IMAB - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas I-Mab Inc.|IMAB - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku I-Mab Biopharma|IMAB - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan I-Mab

Pambiji fundamental perusahaan:I-Mab

Short-term debt reflects the total sum of all financial obligations with a maturity of less than one year. Analyzing aggregate short-term liabilities allows for an assessment of the issuer's current liquidity and solvency. This metric measures the risk of cash flow gaps when servicing accounts payable. For I-Mab (IMAB), this indicator is critical due to a high dependency on external CRO and CMO contractors. Stable debt management ensures uninterrupted funding for the global outsourcing of antibody development.

Pesaing I-Mab (IMAB)